Kurzfassung

Patients with Non-Small Cell Lung Cancer (NSCLC) respond to Immune Checkpoint Blockade (ICB) therapy. T cells infiltrating tumor tissue (“Tumor-infiltrating lymphocytes”, TILs) targeting tumor-associated and tumor-specific antigens have been implicated in the therapeutic effect of ICB. The biotechnology startup company HS Diagnomics has developed and patented a method to identify tumor-specific T cells among polyclonal populations of TILs isolated from NSCLC- and lung surgical specimen. In a...Patients with Non-Small Cell Lung Cancer (NSCLC) respond to Immune Checkpoint Blockade (ICB) therapy. T cells infiltrating tumor tissue (“Tumor-infiltrating lymphocytes”, TILs) targeting tumor-associated and tumor-specific antigens have been implicated in the therapeutic effect of ICB. The biotechnology startup company HS Diagnomics has developed and patented a method to identify tumor-specific T cells among polyclonal populations of TILs isolated from NSCLC- and lung surgical specimen. In a proof-of-concept study this project will use the predicted tumor-specific TILs or T cell receptors isolated from the most promising T cell clonotypes to show their actual tumor reactivity and search for the antigens recognized. The antigen identification program includes Next Generation Sequencing (NGS) analyses, bioinformatic prediction of targets and recognition testing of candidate epitopes as well as cDNA expression screening approaches. This comprehensive program aims at working up the antigenic landscapes recognized by TILs of a small number of NSCLC-patients.» weiterlesen» einklappen